BCL2 Gene Function
BCL2 Apoptosis Regulator
Overview
BCL2 is the founding member of the BCL2 family of apoptosis regulators, functioning as an anti-apoptotic protein that blocks cytochrome c release from mitochondria. Overexpression due to t(14;18) drives follicular lymphoma.
Molecular Mechanism
Mechanism Summary
BCL2 anchors in the outer mitochondrial membrane via its C-terminal hydrophobic tail and sequesters BH3-only proteins (BIM, PUMA, BAD) in its hydrophobic groove, preventing BAX/BAK oligomerisation and cytochrome c release.
Step-by-Step Mechanism
BCL2 (and its relatives BCL-XL, MCL1) constitutively occupies the outer mitochondrial membrane (OMM) via C-terminal transmembrane helix. The BH1, BH2, and BH4 domains form a hydrophobic groove that sequesters pro-apoptotic BH3-only proteins.
Pro-apoptotic stress signals (DNA damage, oncogene activation, growth factor withdrawal) upregulate BH3-only proteins: BIM (BCL2L11), PUMA (BBC3), and NOXA (PMAIP1). These directly bind BCL2's hydrophobic groove, competing with BAX for BCL2 sequestration.
When BH3-only proteins titrate BCL2 beyond its sequestration capacity, BAX (constitutively cycling on/off the OMM) can oligomerise on the OMM. BAK (constitutively mitochondria-anchored) is also released from MCL1/BCL-XL inhibition.
BAX/BAK oligomers insert into the OMM and form large lipidic pores (mitochondrial outer membrane permeabilisation, MOMP). This is the irreversible commitment step to apoptosis, releasing cytochrome c, SMAC/DIABLO, and HTRA2/Omi from the intermembrane space.
Cytochrome c binds APAF1 and (with dATP) drives APAF1 oligomerisation into the heptameric apoptosome, which recruits and activates pro-caspase-9. Active caspase-9 cleaves caspase-3 and caspase-7, executing cellular demolition.
Venetoclax (ABT-199) is a BH3-mimetic that occupies BCL2's hydrophobic groove with high affinity (Ki ~10 pM), directly competing with BH3-only proteins and releasing BAX/BAK for oligomerisation — triggering apoptosis within hours in BCL2-dependent cells.
Upstream Regulators
Places BCL2 under IgH enhancer control, causing ~50-fold BCL2 overexpression in follicular lymphoma
Wild-type p53 represses BCL2 transcription; p53 loss permits BCL2 overexpression
STAT3 directly transcribes BCL2 in lymphoma and carcinoma cells
Downstream Targets
Prevents BH3-only proteins from activating BAX/BAK
BCL2 binding to BAX monomer prevents OMM insertion and oligomerisation
Key Post-Translational Modifications
Anti-apoptotic enhancement; loop domain phosphorylation increases BH3-binding affinity
Proteasomal degradation; limits BCL2 accumulation
Converts BCL2 from anti- to pro-apoptotic; seen in radiation-treated tumours
Disease Mechanism
BCL2 dysregulation is central to follicular lymphoma biology and can contribute to survival in several haematologic malignancies. Some tumours are highly dependent on BCL2 because pro-apoptotic proteins are sequestered near the mitochondrial death threshold, but expression alone does not prove dependency. Venetoclax has current FDA-labelled uses in defined CLL/SLL and AML settings. Resistance can involve alternative anti-apoptotic proteins or changes in the mitochondrial apoptosis machinery.
Database References
Key Pathways
- ·Intrinsic apoptosis pathway
- ·Mitochondrial membrane permeability
- ·BCL2 family regulation
Disease Associations
- ·Follicular lymphoma
- ·Diffuse large B-cell lymphoma
- ·Chronic lymphocytic leukemia
Research Activity
BCL2 is an actively studied target: about 125+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track BCL2 trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About BCL2
What does BCL2 do?
BCL2 is an anti-apoptotic protein that anchors in the outer mitochondrial membrane and sequesters pro-apoptotic BH3-only proteins (BIM, PUMA, BAD), preventing BAX and BAK from oligomerising and forming pores that release cytochrome c. BCL2 therefore blocks the intrinsic apoptotic pathway at the mitochondria.
How does BCL2 cause follicular lymphoma?
The t(14;18) translocation places BCL2 under control of the immunoglobulin heavy-chain enhancer, causing massive BCL2 overexpression in B cells. This blocks normal apoptosis during B-cell development and maturation, allowing cells with additional mutations in MYC, EZH2, or CREBBP to accumulate and form lymphoma.
How does venetoclax work?
Venetoclax (Venclexta) is a BH3-mimetic small molecule that occupies BCL2's hydrophobic groove and can release sequestered pro-apoptotic proteins. The current FDA label covers adults with CLL or SLL and specified combinations for newly diagnosed AML in older adults or those with comorbidities that preclude intensive induction; it is not FDA-approved for multiple myeloma.
Is BCL2 related to p53?
Yes — wild-type p53 transcriptionally represses BCL2 and activates pro-apoptotic BCL2 family members including BAX and PUMA. Loss of p53 therefore permits high BCL2 expression and resistance to apoptosis induction by chemotherapy — one reason TP53-mutant tumours are often chemoresistant.